Login to Your Account



Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth

By Jennifer Boggs


Monday, January 29, 2007
Despite topping revenue estimates for the fourth quarter, Amgen's Inc.'s stock slipped more than $3 on news of unsettling Phase III Aranesp data. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription